News | May 06, 2014

CardioInsight's Non-Invasive 3-D Cardiac Mapping Featured at HRS 2014

May 6, 2014 — CardioInsight Technologies Inc.’s Ecvue system will be featured at the Rhythm Theatre Symposium and in 17 abstract presentations at the upcoming 2014 Heart Rhythm Society Annual Scientific Sessions in San Francisco. 

The Rhythm Theatre Symposium highlights promising results from European clinical studies using the company's non-invasive mapping for persistent atrial fibrillation in more than 300 patients. The symposium, chaired by Francis Marchlinski (University of Pennsylvania Medical Center), will be held Wednesday, May 7, from 6:15-7:15 p.m. in Rhythm Theatre #2, and include presentations from Dr. Douglas Packer (Mayo Clinic), Dr. Michel Haissaguerre (CHU Bordeaux) and Dr. Sebastien Knecht (CHU Brugmann, Brussels). Topics include:

  • Clinical AF Mapping:  Back to the Future (Douglas L. Packer, M.D.)
  • A Practical Approach to AF Mapping:  AFACART EU Multicenter Study Results (Sebastien Knecht, M.D.)
  • The Bordeaux Experience (Michel Haissaguerre, M.D.)
  • Common Clinical Questions & Practical Considerations (Francis Marchlinski, M.D.)

* Ecvue is not yet cleared or approved for use by the U.S. Food and Drug Administration (FDA). Ecvue has received CE mark.

For more information: www.cardioinsight.com

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Overlay Init